Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Bre... (b is in clinical trials in the U.S.in pa...)

HOME >> MEDICINE >> TECHNOLOGY

Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer

Date:1/29/2008

b is in clinical trials in the U.S. in patients with advanced solid tumors and in patients co- infected with HCV and HIV.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the company will experience delays or difficulties in enrolling patients in the study, the risk that the standard docetaxel response rate will not be improved as a result of the combination therapy, and the risk that the results from this trial will not be consistent with the results of prior trials or preclinical studies. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
3. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
4. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
5. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
6. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
10. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)

Post Your Comments:

(Date:11/30/2009)...wswire-FirstCall/ -- Covance Inc. (NYSE: CVD ) t...affray 21st Annual Health Care Conference on Wedne...rs may access a live webcast of the presentation a...nload any necessary software, please log on 10 min...inceton, New Jersey, is one of the world,s largest...

(Date:11/30/2009)...RNewswire/ -- The Eleventh Annual Southeastern BIO... Charleston Place Hotel in the historic district o...yl Liljestrand, Dr. Harry Guttman, and Dr. Jeremy ...ill attend. SEBIO 2009 promises to bring innovati...entrepreneurs, and service providers from around t...

(Date:11/30/2009)...swire-FirstCall/ -- Henry Schein, Inc., (Nasdaq: ...ts and services, announced today that Steven Palad...ief Financial Officer, will present at the NASDAQ ...2009. The conference is taking place at the Mayfa...tion is scheduled to begin at 9:15 a.m. EST and ca...

Breaking Medicine Technology:Henry Schein to Present at the NASDAQ OMX 23rd Investor Program 2 Consumer Reports Poll 3A 43 25 of Americans Say Theyre on the Fence about Swine Flu Vaccine 58595 1 Consumer Reports Poll 3A 43 25 of Americans Say Theyre on the Fence about Swine Flu Vaccine 58595 2 Consumer Reports Poll 3A 43 25 of Americans Say Theyre on the Fence about Swine Flu Vaccine 58595 3 Consumer Reports Poll 3A 43 25 of Americans Say Theyre on the Fence about Swine Flu Vaccine 58595 4 Commercial Insurance Buyers Benefit From Ample Capacity 14306 1 Commercial Insurance Buyers Benefit From Ample Capacity 14306 2 Commercial Insurance Buyers Benefit From Ample Capacity 14306 3 Cardiac stem cell trial seeks to treat some heart attack patients 58592 1 Cardiac stem cell trial seeks to treat some heart attack patients 58592 2 Cardiac stem cell trial seeks to treat some heart attack patients 58592 3

[0] Covance to Present at Piper Jaffray 21st Annual Health Care Conference [0] Stipkala LLC to Sponsor SEBIO 2009 [0] Henry Schein to Present at the NASDAQ OMX 23rd Investor Program

...f $81.4 Million, RICHMOND, Calif., Feb. 5 Sangam... 2007 fourth quarter and year-end,financial result...2008., For the fourth quarter ended December 31, ...$6.7 million, or $0.17 per share, compared to a,ne...e same period in 2006.,As of December 31, 2007, th...

...ng innovative therapeutics for sickle cell anemia ...ogression, such as the important role,of hydration...ublished,online in Blood, the official journal of ...molecule therapy called senicapoc showed efficacy,...creasing hemoglobin,levels in patients with sickle...

Other Medicine Technology:Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results 2 Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results 3 Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results 4 Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results 5 Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results 6 Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results 7 Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results 8 Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells 2 Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells 3

Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells

(Date:12/1/2009)...Dec. 1 To date, hospitals have not... them for the $20 cost of the disposable sensor fo.... ,, Anesthesiologists have not told hospitals ...dementia from routine anesthesia over-medication. ...over-medication, message from their leaders becaus...

(Date:12/1/2009)...RNewswire-FirstCall/ -- Cell Therapeutics, Inc. (C...on at the 21st Annual Piper Jaffray Health Care Co...ern Time will be webcast live at www.celltherapeu...e in Holmes 1 at the New York Palace Hotel, and wi...tion. , , Piper Jaffray Heal...

(Date:12/1/2009)... the annual meeting of the Radiological Society of...y accurate means of identifying placenta accreta, ...mmon condition that is the leading cause of death ... "Due to the increase in cesarean sections and oth...ll, coupled with women giving birth later in life,...

(Date:12/1/2009)...ontrolled clinical trial presented today at the an...America (RSNA) reveal that one in five patients wi...lood to the legs and other parts of the body also ...e. , Peripheral arterial disease (PAD) occurs w...other substances, builds up in the arteries, limit...

(Date:12/1/2009)...viation-related injuries and deaths in the U.S. fi...U.S. hospitals with aviation-related injuries annu.... The study, conducted by researchers from the Joh...ter for Injury Research and Policy and Columbia Un... of patients were occupants of civilian, noncommer...

Breaking Medicine News(10 mins):Health News:5 Shocking Reasons Your Brain Isn't Worth Twenty Bucks Exposed 2 Health News:MRI helps detect life-threatening pregnancy complication 2 Health News:Severe asymptomatic heart disease may accompany narrowing in leg arteries 2 Health News:More than 1,000 patients in US admitted annually for aviation-related injuries 2

[0] 5 Shocking Reasons Your Brain Isn't Worth Twenty Bucks Exposed [0] Cell Therapeutics, Inc. (CTI) Piper Jaffray Presentation to be Webcast [0] MRI helps detect life-threatening pregnancy complication [0] Severe asymptomatic heart disease may accompany narrowing in leg arteries [0] More than 1,000 patients in US admitted annually for aviation-related injuries

...tion,Agency has announced that two Michigan asthma... Michigan in Grand Rapids and the University of,Mi...ee programs nationwide,to win EPA,s 2008 National ...e models for the rest of the country," said EPA,Re...

...r Improve in 86% at Six Months, TORONTO, May 9 /P....,(TSX: NDQ), a developer of real-time imaging and...oom, today announced that independent data was,pre...from two of the three European hospitals currently...

...lace an,employee can be as high as 2.41% of annual...n,s Service-Profit Chain is even higher. A benchma...effects of turnover on the,bottom line and offers ... from the report, a reduction in turnover,rates by...

...DRAXIS Health Inc. (TSX: DAX),(NASDAQ: DRAX ) rep...e,months ended March 31, 2008. Revenues and earnin...in the first quarter of 2007 as a result of lower,...,first quarter of 2007 of non-recurring items and ...

... 4,000 infection prevention and control profession...at a five-day conference next month to discuss man...y. , Strategies for infection prevention, best pr...ill be covered at the Association for Professional...

... the,history of Myanmar, the tropical Cyclone Narg...including its capital Yangon on Friday, May 2, 200...d and the death toll is,spiraling up, minute by mi...r area is about 24 million., Since there is no wa...

Two Michigan Asthma Management Programs Win EPA National Award Novadaq's OPTTX System Data Presented at ARVO Employee Engagement & Retention: Benchmarking Metrics and Networking Opportunity to Help Solve Today's Workforce Challenges DRAXIS Health Reports Results for the First Quarter of 2008 APIC conference to focus on patient safety and 'Targeting Zero' initiatives to reduce HAIs Myanmar Cyclone Relief Fund

Double LASIK Flap Irrigation Cannula

LASIK Irrigating Cannula

LASIK Flap Irrigator

Guiber CIS Se

Medicine Products:

Double LASIK Flap Irrigation Cannula LASIK Irrigating Cannula LASIK Flap Irrigator Guiber CIS Se

Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Bre...(b is in clinical trials in the U.S.in pa...),Health